Comparative Evaluation of Neuroprotective Activity of Tryptanthrin and Its Oxime in Middle Cerebral Artery Occlusion in Rats
The neuroprotective activity of tryptanthrin and its oxime was compared in male Wistar rats with a model of intraluminal occlusion of the middle cerebral artery. Neurobehavioral tests were performed 4, 24, and 48 h after focal cerebral infarction (FCI) using a modified neurological severity score (m...
Gespeichert in:
| Veröffentlicht in: | Bulletin of experimental biology and medicine 2024-07, Vol.177 (3), p.344-348 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 348 |
|---|---|
| container_issue | 3 |
| container_start_page | 344 |
| container_title | Bulletin of experimental biology and medicine |
| container_volume | 177 |
| creator | Chernysheva, G. A. Smolyakova, V. I. Plotnikov, M. B. Ulyakhina, O. A. Osipenko, A. N. Kovrizhina, A. R. Khlebnikov, A. I. |
| description | The neuroprotective activity of tryptanthrin and its oxime was compared in male Wistar rats with a model of intraluminal occlusion of the middle cerebral artery. Neurobehavioral tests were performed 4, 24, and 48 h after focal cerebral infarction (FCI) using a modified neurological severity score (mNSS); additionally, the horizontal stability test, the plantar sensitivity test of the fore and hind limbs, holding on the tilted cage top test, and negative geotaxis test were performed. The size of FCI and the severity of brain tissue swelling were examined on day 2 after occlusion. Tryptanthrin and its oxime were administered at a dose of 10 mg/kg intraperitoneally during FCI, then daily for 2 days. In the control group, the mean score of neurological deficit remained at a high level for 2 days. FCI size was 43.8±3.4% of hemisphere area, and the hemisphere volume increased by 18.5±2.0% due to brain tissue swelling and edema. Administration of tryptanthrin and its oxime significantly decreased neurological deficits at all control points and reduced FCI size (by 24.2 and 30.4%, respectively) and brain tissue swelling of the affected hemisphere (by 64.9 and 62.7%, respectively). Therefore, the neuroprotective effect of tryptanthrine and its oxime in the acute period of FCI is largely determined by their anti-inflammatory activity. |
| doi_str_mv | 10.1007/s10517-024-06186-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3091288106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3097584242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-ce8fd1ef55d78236852205c016516d1740b872f91895bf906c815561a3fd539b3</originalsourceid><addsrcrecordid>eNp9kU9P3DAQxa2KqmxpvwCHyhKXXlI8Tuw4x9VqC0iUlRCcLceZlKD82drOQiQ-PA5LQeqhp7H9fvPG9iPkGNgPYCw_9cAE5AnjWcIkKJk8fCALEHmaKM7hgCxYpJJMKXVIPnt_P28j-IkcpgVwKTK5IE-rodsaZ0KzQ7remXaMy6GnQ02vcHTD1g0B7Yu6nEsTplm7cdM2mD7cuaanpq_oRfB089h0SOPBr6aqWqQrdFg609KlC-gmurG2Hf3sHplrE_wX8rE2rcevr_WI3P5c36zOk8vN2cVqeZlYLmRILKq6AqyFqHLFU6kE50xYBlKArCDPWKlyXhegClHWBZNWgRASTFpXIi3K9Ih83_vG1_wZ0QfdNd5i25oeh9HrlMX_UAqYjOjJP-j9MLo-3m6mcqEynvFI8T1l3eC9w1pvXdMZN2lges5G77PRMRv9ko1-iE3fXq3HssPqreVvGBFI94CPUv8b3fvs_9g-A5Dgmkc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097584242</pqid></control><display><type>article</type><title>Comparative Evaluation of Neuroprotective Activity of Tryptanthrin and Its Oxime in Middle Cerebral Artery Occlusion in Rats</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Chernysheva, G. A. ; Smolyakova, V. I. ; Plotnikov, M. B. ; Ulyakhina, O. A. ; Osipenko, A. N. ; Kovrizhina, A. R. ; Khlebnikov, A. I.</creator><creatorcontrib>Chernysheva, G. A. ; Smolyakova, V. I. ; Plotnikov, M. B. ; Ulyakhina, O. A. ; Osipenko, A. N. ; Kovrizhina, A. R. ; Khlebnikov, A. I.</creatorcontrib><description>The neuroprotective activity of tryptanthrin and its oxime was compared in male Wistar rats with a model of intraluminal occlusion of the middle cerebral artery. Neurobehavioral tests were performed 4, 24, and 48 h after focal cerebral infarction (FCI) using a modified neurological severity score (mNSS); additionally, the horizontal stability test, the plantar sensitivity test of the fore and hind limbs, holding on the tilted cage top test, and negative geotaxis test were performed. The size of FCI and the severity of brain tissue swelling were examined on day 2 after occlusion. Tryptanthrin and its oxime were administered at a dose of 10 mg/kg intraperitoneally during FCI, then daily for 2 days. In the control group, the mean score of neurological deficit remained at a high level for 2 days. FCI size was 43.8±3.4% of hemisphere area, and the hemisphere volume increased by 18.5±2.0% due to brain tissue swelling and edema. Administration of tryptanthrin and its oxime significantly decreased neurological deficits at all control points and reduced FCI size (by 24.2 and 30.4%, respectively) and brain tissue swelling of the affected hemisphere (by 64.9 and 62.7%, respectively). Therefore, the neuroprotective effect of tryptanthrine and its oxime in the acute period of FCI is largely determined by their anti-inflammatory activity.</description><identifier>ISSN: 0007-4888</identifier><identifier>ISSN: 1573-8221</identifier><identifier>EISSN: 1573-8221</identifier><identifier>DOI: 10.1007/s10517-024-06186-w</identifier><identifier>PMID: 39126546</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Animal models ; Animals ; Anti-inflammatory agents ; Biomedical and Life Sciences ; Biomedicine ; Brain - drug effects ; Brain - pathology ; Brain Edema - drug therapy ; Brain Edema - pathology ; Brain research ; Carotid arteries ; Cell Biology ; Cerebral blood flow ; Cerebral infarction ; Disease Models, Animal ; Drug dosages ; Edema ; Geotaxis ; Infarction, Middle Cerebral Artery - drug therapy ; Infarction, Middle Cerebral Artery - pathology ; Internal Medicine ; Ischemia ; Laboratory Medicine ; Limbs ; Male ; Medical research ; Neurological diseases ; Neuroprotection ; Neuroprotective Agents - pharmacology ; Neuroprotective Agents - therapeutic use ; Oximes - pharmacology ; Oximes - therapeutic use ; Pathology ; Pharmacology ; Quinazolines - pharmacology ; Quinazolines - therapeutic use ; Rats ; Rats, Wistar ; Regenerative medicine ; Sensitivity analysis ; Stroke ; Veins & arteries</subject><ispartof>Bulletin of experimental biology and medicine, 2024-07, Vol.177 (3), p.344-348</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-ce8fd1ef55d78236852205c016516d1740b872f91895bf906c815561a3fd539b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10517-024-06186-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10517-024-06186-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39126546$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chernysheva, G. A.</creatorcontrib><creatorcontrib>Smolyakova, V. I.</creatorcontrib><creatorcontrib>Plotnikov, M. B.</creatorcontrib><creatorcontrib>Ulyakhina, O. A.</creatorcontrib><creatorcontrib>Osipenko, A. N.</creatorcontrib><creatorcontrib>Kovrizhina, A. R.</creatorcontrib><creatorcontrib>Khlebnikov, A. I.</creatorcontrib><title>Comparative Evaluation of Neuroprotective Activity of Tryptanthrin and Its Oxime in Middle Cerebral Artery Occlusion in Rats</title><title>Bulletin of experimental biology and medicine</title><addtitle>Bull Exp Biol Med</addtitle><addtitle>Bull Exp Biol Med</addtitle><description>The neuroprotective activity of tryptanthrin and its oxime was compared in male Wistar rats with a model of intraluminal occlusion of the middle cerebral artery. Neurobehavioral tests were performed 4, 24, and 48 h after focal cerebral infarction (FCI) using a modified neurological severity score (mNSS); additionally, the horizontal stability test, the plantar sensitivity test of the fore and hind limbs, holding on the tilted cage top test, and negative geotaxis test were performed. The size of FCI and the severity of brain tissue swelling were examined on day 2 after occlusion. Tryptanthrin and its oxime were administered at a dose of 10 mg/kg intraperitoneally during FCI, then daily for 2 days. In the control group, the mean score of neurological deficit remained at a high level for 2 days. FCI size was 43.8±3.4% of hemisphere area, and the hemisphere volume increased by 18.5±2.0% due to brain tissue swelling and edema. Administration of tryptanthrin and its oxime significantly decreased neurological deficits at all control points and reduced FCI size (by 24.2 and 30.4%, respectively) and brain tissue swelling of the affected hemisphere (by 64.9 and 62.7%, respectively). Therefore, the neuroprotective effect of tryptanthrine and its oxime in the acute period of FCI is largely determined by their anti-inflammatory activity.</description><subject>Animal models</subject><subject>Animals</subject><subject>Anti-inflammatory agents</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain - drug effects</subject><subject>Brain - pathology</subject><subject>Brain Edema - drug therapy</subject><subject>Brain Edema - pathology</subject><subject>Brain research</subject><subject>Carotid arteries</subject><subject>Cell Biology</subject><subject>Cerebral blood flow</subject><subject>Cerebral infarction</subject><subject>Disease Models, Animal</subject><subject>Drug dosages</subject><subject>Edema</subject><subject>Geotaxis</subject><subject>Infarction, Middle Cerebral Artery - drug therapy</subject><subject>Infarction, Middle Cerebral Artery - pathology</subject><subject>Internal Medicine</subject><subject>Ischemia</subject><subject>Laboratory Medicine</subject><subject>Limbs</subject><subject>Male</subject><subject>Medical research</subject><subject>Neurological diseases</subject><subject>Neuroprotection</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Oximes - pharmacology</subject><subject>Oximes - therapeutic use</subject><subject>Pathology</subject><subject>Pharmacology</subject><subject>Quinazolines - pharmacology</subject><subject>Quinazolines - therapeutic use</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Regenerative medicine</subject><subject>Sensitivity analysis</subject><subject>Stroke</subject><subject>Veins & arteries</subject><issn>0007-4888</issn><issn>1573-8221</issn><issn>1573-8221</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9P3DAQxa2KqmxpvwCHyhKXXlI8Tuw4x9VqC0iUlRCcLceZlKD82drOQiQ-PA5LQeqhp7H9fvPG9iPkGNgPYCw_9cAE5AnjWcIkKJk8fCALEHmaKM7hgCxYpJJMKXVIPnt_P28j-IkcpgVwKTK5IE-rodsaZ0KzQ7remXaMy6GnQ02vcHTD1g0B7Yu6nEsTplm7cdM2mD7cuaanpq_oRfB089h0SOPBr6aqWqQrdFg609KlC-gmurG2Hf3sHplrE_wX8rE2rcevr_WI3P5c36zOk8vN2cVqeZlYLmRILKq6AqyFqHLFU6kE50xYBlKArCDPWKlyXhegClHWBZNWgRASTFpXIi3K9Ih83_vG1_wZ0QfdNd5i25oeh9HrlMX_UAqYjOjJP-j9MLo-3m6mcqEynvFI8T1l3eC9w1pvXdMZN2lges5G77PRMRv9ko1-iE3fXq3HssPqreVvGBFI94CPUv8b3fvs_9g-A5Dgmkc</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Chernysheva, G. A.</creator><creator>Smolyakova, V. I.</creator><creator>Plotnikov, M. B.</creator><creator>Ulyakhina, O. A.</creator><creator>Osipenko, A. N.</creator><creator>Kovrizhina, A. R.</creator><creator>Khlebnikov, A. I.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20240701</creationdate><title>Comparative Evaluation of Neuroprotective Activity of Tryptanthrin and Its Oxime in Middle Cerebral Artery Occlusion in Rats</title><author>Chernysheva, G. A. ; Smolyakova, V. I. ; Plotnikov, M. B. ; Ulyakhina, O. A. ; Osipenko, A. N. ; Kovrizhina, A. R. ; Khlebnikov, A. I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-ce8fd1ef55d78236852205c016516d1740b872f91895bf906c815561a3fd539b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Anti-inflammatory agents</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain - drug effects</topic><topic>Brain - pathology</topic><topic>Brain Edema - drug therapy</topic><topic>Brain Edema - pathology</topic><topic>Brain research</topic><topic>Carotid arteries</topic><topic>Cell Biology</topic><topic>Cerebral blood flow</topic><topic>Cerebral infarction</topic><topic>Disease Models, Animal</topic><topic>Drug dosages</topic><topic>Edema</topic><topic>Geotaxis</topic><topic>Infarction, Middle Cerebral Artery - drug therapy</topic><topic>Infarction, Middle Cerebral Artery - pathology</topic><topic>Internal Medicine</topic><topic>Ischemia</topic><topic>Laboratory Medicine</topic><topic>Limbs</topic><topic>Male</topic><topic>Medical research</topic><topic>Neurological diseases</topic><topic>Neuroprotection</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Oximes - pharmacology</topic><topic>Oximes - therapeutic use</topic><topic>Pathology</topic><topic>Pharmacology</topic><topic>Quinazolines - pharmacology</topic><topic>Quinazolines - therapeutic use</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Regenerative medicine</topic><topic>Sensitivity analysis</topic><topic>Stroke</topic><topic>Veins & arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chernysheva, G. A.</creatorcontrib><creatorcontrib>Smolyakova, V. I.</creatorcontrib><creatorcontrib>Plotnikov, M. B.</creatorcontrib><creatorcontrib>Ulyakhina, O. A.</creatorcontrib><creatorcontrib>Osipenko, A. N.</creatorcontrib><creatorcontrib>Kovrizhina, A. R.</creatorcontrib><creatorcontrib>Khlebnikov, A. I.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Bulletin of experimental biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chernysheva, G. A.</au><au>Smolyakova, V. I.</au><au>Plotnikov, M. B.</au><au>Ulyakhina, O. A.</au><au>Osipenko, A. N.</au><au>Kovrizhina, A. R.</au><au>Khlebnikov, A. I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative Evaluation of Neuroprotective Activity of Tryptanthrin and Its Oxime in Middle Cerebral Artery Occlusion in Rats</atitle><jtitle>Bulletin of experimental biology and medicine</jtitle><stitle>Bull Exp Biol Med</stitle><addtitle>Bull Exp Biol Med</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>177</volume><issue>3</issue><spage>344</spage><epage>348</epage><pages>344-348</pages><issn>0007-4888</issn><issn>1573-8221</issn><eissn>1573-8221</eissn><abstract>The neuroprotective activity of tryptanthrin and its oxime was compared in male Wistar rats with a model of intraluminal occlusion of the middle cerebral artery. Neurobehavioral tests were performed 4, 24, and 48 h after focal cerebral infarction (FCI) using a modified neurological severity score (mNSS); additionally, the horizontal stability test, the plantar sensitivity test of the fore and hind limbs, holding on the tilted cage top test, and negative geotaxis test were performed. The size of FCI and the severity of brain tissue swelling were examined on day 2 after occlusion. Tryptanthrin and its oxime were administered at a dose of 10 mg/kg intraperitoneally during FCI, then daily for 2 days. In the control group, the mean score of neurological deficit remained at a high level for 2 days. FCI size was 43.8±3.4% of hemisphere area, and the hemisphere volume increased by 18.5±2.0% due to brain tissue swelling and edema. Administration of tryptanthrin and its oxime significantly decreased neurological deficits at all control points and reduced FCI size (by 24.2 and 30.4%, respectively) and brain tissue swelling of the affected hemisphere (by 64.9 and 62.7%, respectively). Therefore, the neuroprotective effect of tryptanthrine and its oxime in the acute period of FCI is largely determined by their anti-inflammatory activity.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>39126546</pmid><doi>10.1007/s10517-024-06186-w</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-4888 |
| ispartof | Bulletin of experimental biology and medicine, 2024-07, Vol.177 (3), p.344-348 |
| issn | 0007-4888 1573-8221 1573-8221 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3091288106 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Animal models Animals Anti-inflammatory agents Biomedical and Life Sciences Biomedicine Brain - drug effects Brain - pathology Brain Edema - drug therapy Brain Edema - pathology Brain research Carotid arteries Cell Biology Cerebral blood flow Cerebral infarction Disease Models, Animal Drug dosages Edema Geotaxis Infarction, Middle Cerebral Artery - drug therapy Infarction, Middle Cerebral Artery - pathology Internal Medicine Ischemia Laboratory Medicine Limbs Male Medical research Neurological diseases Neuroprotection Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Oximes - pharmacology Oximes - therapeutic use Pathology Pharmacology Quinazolines - pharmacology Quinazolines - therapeutic use Rats Rats, Wistar Regenerative medicine Sensitivity analysis Stroke Veins & arteries |
| title | Comparative Evaluation of Neuroprotective Activity of Tryptanthrin and Its Oxime in Middle Cerebral Artery Occlusion in Rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T04%3A42%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20Evaluation%20of%20Neuroprotective%20Activity%20of%20Tryptanthrin%20and%20Its%20Oxime%20in%20Middle%20Cerebral%20Artery%20Occlusion%20in%20Rats&rft.jtitle=Bulletin%20of%20experimental%20biology%20and%20medicine&rft.au=Chernysheva,%20G.%20A.&rft.date=2024-07-01&rft.volume=177&rft.issue=3&rft.spage=344&rft.epage=348&rft.pages=344-348&rft.issn=0007-4888&rft.eissn=1573-8221&rft_id=info:doi/10.1007/s10517-024-06186-w&rft_dat=%3Cproquest_cross%3E3097584242%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3097584242&rft_id=info:pmid/39126546&rfr_iscdi=true |